Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
2 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
3 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
4 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
5 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
6 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
7 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
8 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
9 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
10 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
11 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
12 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
13 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
14 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
15 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
16 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
17 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa [5] 5, 6, 17, 169, 170
18 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
19 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
20 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D02004 Apomorphine [3] 5, 6, 7
21 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D07460 Apomorphine [3] 5, 6, 7
22 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D02004 Apomorphine [3] 5, 6, 7
23 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07460 Apomorphine [3] 5, 6, 7
24 ABAT [7] Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
25 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
26 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06378 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
27 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06379 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
28 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
29 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
30 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
31 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
32 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
33 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
34 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
35 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
36 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
37 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
38 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
39 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
40 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
41 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
42 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
43 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
44 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
45 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
46 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
47 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
48 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
49 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
50 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
51 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
52 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
53 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
54 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
55 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
56 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
57 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
58 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
59 GAD1 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
60 GAD2 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
61 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
62 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
63 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
64 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
65 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
66 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
67 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
68 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
69 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
70 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
71 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
72 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
73 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
74 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
75 HCRTR1 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [3] 5, 6, 13
76 HCRTR2 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [3] 5, 6, 13
77 KIT [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib [6] 2, 5, 6, 13, 46, 96
78 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02562 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
79 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08469 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
80 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10829 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
81 MAPT [4] MAPK signaling pathway, Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases D11210 Flortaucipir [3] 5, 7, 127
82 MAPT [4] MAPK signaling pathway, Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases D11293 Gosuranemab [1] 5
83 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D00670 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
84 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D02558 Rivastigmine [3] 5, 6, 13
85 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine [3] 5, 6, 13
86 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
87 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
88 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
89 PTGS1 [5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00428 Salsalate [1] 5
90 PTGS1 [5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01183 Tolfenamic acid [1] 5
91 PTGS2 [22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00428 Salsalate [1] 5
92 PTGS2 [22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01183 Tolfenamic acid [1] 5
93 ROCK1 [20] cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, TGF-beta signaling pathway, Axon guidance, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer D07941 Fasudil [4] 2, 5, 7, 51
94 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A [13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226
95 ALDH5A1 [3] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
96 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
97 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
98 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
99 ROCK2 [21] cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Axon guidance, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D07941 Fasudil [4] 2, 5, 7, 51